Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

InveniAI Enters Strategic AI Collaboration with Kyowa Hakko Kirin

Focus on leveraging the power of AI to expand the therapeutic index of existing portfolio

Related Posts
1 of 41,175

InveniAI Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across healthcare and other industries, is pleased to announce it has entered a collaboration agreement with Kyowa Hakko Kirin Co., Ltd. to harness the power of AI and ML for drug discovery. Through this collaboration, Kyowa Hakko Kirin, a life sciences company with a focus on new biologics and medicines for unmet medical needs, will leverage InveniAI’s platform – AlphaMeld™ – to maximize portfolio value through the re-innovation of an existing therapeutic pipeline into new disease indications.

Read More: Setting the Stage Now for Artificial Intelligence Success in 2019

Mitsuo Satoh, Ph.D., Executive Officer, Vice President, Head, R&D Division of Kyowa Hakko Kirin said, “As we seek to fulfill our business vision to bring innovative treatments to patients faster, we very much expect that InveniAI’s platform, will not only enable us to identify alternate therapeutic value for our portfolio at an unprecedented speed, but also capitalize on our existing investment by reducing the time to market, clinical cost of development and enhancing the probability of clinical success.”

Read More: FreakOut Announces Expansion, Appoints New Leadership Team in Russia & CIS, Middle East and Australasia

Krishnan Nandabalan, Ph.D., CEO and President of InveniAI said, “We are extremely pleased to initiate this collaboration to build on Kyowa Hakko Kirin’s clinically rich pipeline. AlphaMeld has industrialized the process of drug re-innovation by enabling the identification of complex associations between drugs/mechanisms and disease indications. The platform is patient-validated where multiple drug concepts have progressed through to human proof of clinical development.”

Under the terms of the collaboration, InveniAI will receive an upfront payment as well as development milestones and commercialization payments.  Financial details are not disclosed.

Read More: Five9 Customer Service Index 2018 Reveals a Rise in Customer Expectations and Willingness to Share Data

1 Comment
  1. Copper recycling plant says

    Scrap Copper recycling centers Sustainable copper processing Metal reprocessing and recovery
    Copper cable recovery methodologies, Metal recovery and reprocessing facility, Regulatory compliance for copper recycling

Leave A Reply

Your email address will not be published.